C-reactive protein (CRP) is a predictor of cardiovascular risk. It circulates as a pentamer (pentameric CRP) in plasma. The in vivo existence of monomeric (m)CRP has been postulated, but its function and source are not clear. We show that mCRP is deposited in human aortic and carotid atherosclerotic plaques but not in healthy vessels. pCRP is found neither in healthy nor in diseased vessels. As source of mCRP, we identify a mechanism of dissociation of pCRP to mCRP. We report that activated platelets, which play a central role in cardiovascular events, mediate this dissociation via lysophosphatidylcholine, which is present on activated but not resting platelets. Furthermore, the dissociation of pCRP to mCRP can also be mediated by apoptotic monocytic THP-1 and Jurkat T cells. The functional consequence is the unmasking of proinflammatory effects of CRP as demonstrated in experimental settings that are pathophysiologically relevant for atherogenesis: compared to pCRP, mCRP induces enhanced monocyte chemotaxis; monocyte activation, as determined by conformational change of integrin Mac-1; generation of reactive oxygen species; and monocyte adhesion under static and physiological flow conditions. In conclusion, we demonstrate mCRP generation via pCRP dissociation on activated platelets and H 2 O 2 -treated apoptotic THP-1 and Jurkat T cells, thereby identifying a mechanism of localized unmasking of the proinflammatory properties of CRP. This novel mechanism provides a potential link between the established cardiovascular risk marker, circulating pCRP, and localized platelet-mediated inflammatory and proatherogenic effects. (Circ Res. 2009;105:128-137.) 
C -reactive protein (CRP) is a highly conserved protein of the pentraxin family that consists of 5 noncovalently linked subunits of Ϸ23 kDa. It is mainly produced in the liver, but under certain conditions can also be secreted by smooth muscle cells 1 and endothelial cells. 2 It was first discovered as an acute phase reactant, with plasma levels increasing from a baseline level of 1 to 2 g/mL up to 100-to 1000-fold within 24 to 72 hours. Because of this rapid cytokinedriven response to tissue injury, infection, and inflammation, CRP is seen as the prototypic inflammatory marker.
Small, 2-to 5-fold increases in the baseline level of plasma CRP in asymptomatic individuals have been associated with an increased risk for cardiovascular events such as stroke and myocardial infarction. 3, 4 In the recently published Jupiter trial, mildly elevated CRP levels were used to guide primary prevention, resulting in a significant reduction of major cardiovascular events in apparently healthy individuals. 5 Although the exact role of CRP in atherosclerosis and its complications are unknown, evidence is now emerging to suggest that it may be a direct, causative factor. 6, 7 In vitro, CRP has been reported to increase interleukin-8 production in monocytes, 8 inhibit endothelial nitric oxide synthase, 9 alter the antioxidant defenses, and promote apoptosis in endothelial progenitor cells. 10 CRP increases monocyte adhesion to human endothelial cells under flow conditions. 11 CRP has also been shown to be released from vulnerable plaques, 12 where it colocalizes with macrophages, oxidized LDL, and complement factors. 13, 14 In human plasma, CRP exists as a cyclic, disc-shaped pentamer of 115 kDa (pentameric pCRP). However, it has been postulated that pCRP can undergo dissociation, thereby acquiring distinct functionality. 15 This alternative conformation of CRP has been termed modified or monomeric (m)CRP and has a distinct solubility (tending to be a nonsoluble tissue-based protein rather than a soluble plasma-based protein), with antigenicity-expressing neoepitopes differing from native pCRP epitopes. The dissociation process of pCRP can occur spontaneously and therefore previous results based on nonspecified CRP preparations could reflect the activity of Figure 1 . mCRP can be detected in fatty streak lesions and fibrofatty plaques of the human aorta but not in healthy vessels. Antibody clone 8, which recognizes both pCRP-and mCRP; conformation-specific antibodies 9C9 (mCRP) and clone 8D8 (pCRP); anti-CD68 antibody (macrophages); and anti-CD41 antibody (platelets) were used. Goat anti-mouse horseradish peroxidase-coupled antibody was used as secondary antibody. Isotype-matched nonspecific mouse IgG served as control. Representative results are shown (nϭ3 for each sample). Images were taken in ϫ100 magnification, and ϫ400 high-power fields are shown within the sections.
either conformation alone or the combination of both. This is important because there is growing evidence that pCRP and mCRP differ in their biological effects: in contrast to pCRP, mCRP induces interleukin-8 secretion in neutrophils 16 and human coronary artery endothelial cells, 17 promotes neutrophil-endothelial cell adhesion, 18 and de-lays apoptosis of human neutrophils. 19 Additionally, both CRP conformations interact differently with components of the complement cascade. 20 Despite the growing interest in mCRP, it remains unclear how mCRP is generated and whether it contributes to inflammatory processes such as atherosclerosis. Figure 2 . A, Activated platelets dissociate pCRP in a LPCdependent process. pCRP (50 g/mL) was incubated with either purified activated or nonactivated platelets or on a monolayer of either LPC and PC or PC alone. Dissociation of pCRP under these conditions was assessed in a Western blot of native PAGE, and both pCRP and mCRP were detected with the anti-CRP antibody clone 8. The newly formed mCRP is not found in the supernatant of activated platelets, suggesting that it is bound to platelets. A monolayer of LPC and PC, as a model for an activated membrane, leads to dissociation of pCRP but not a monolayer of PC alone. The correct size of proteins was confirmed by artificially dissociated pCRP and nondissociated pCRP. B, pCRP dissociation on activated platelets in whole blood. pCRP was added to whole blood, stimulated or not with 20 mol/L ADP, incubated for 120 minutes, and then loaded on nondenaturing gels. As control, whole blood was loaded directly after supplementing with pCRP. mCRP formation was detected by Western blotting and staining with CRP-specific antibodies. C, Dissociation of pCRP on activated platelets leads to increased monocyte adhesion. pCRP (25 g/mL) was dissociated into monomers on activated platelets for 30 minutes at 37°C. Monocytes were stimulated with either this mixture or nonactivated platelets plus pCRP, pCRP alone, pCRP plus ADP, platelets alone, or ADP-stimulated platelets for 30 minutes at 37°C and allowed to adhere to fibrinogen (50 g/mL) in 96-well plates. Phorbol 12-myristate 13-acetate (PMA)-stimulated (100 ng/mL) monocytes served as positive control; monocyte adhesion to noncoated wells served as blank. Adherent cells were quantified with a phosphatase-substrate assay, and absorbance was read at 405 nm. Results of 5 independent experiments, each performed in triplicate, were averaged, with absorption of PMA-stimulated monocytes being 100%. #PϽ0.01 compared to control. Adhesion of nonstimulated monocytes to fibrinogen served as control. D, An artificial LPC-PC monolayer leads to pCRP dissociation and increases monocyte adhesion. pCRP (25 g/mL) was dissociated into monomers on an immobilized LPC-PC monolayer in PBS-Ca-Mg for 30 minutes at 37°C. The supernatant was taken off and monocytes were stimulated with this mixture or incubated with pCRP, pCRP incubated with immobilized PC, or each of the lipids alone and allowed to adhere to a 96-well plate coated with fibrinogen. Monocyte adhesion to uncoated wells served as blank. Results of 5 independent experiments, each performed in triplicate, were averaged, with absorption of PMA-stimulated monocytes being 100%. #PϽ0.01 compared to the control of nonstimulated monocytes. E, The activated platelet membrane is the mediator of the receptor-independent dissociation process. pCRP (50 g/mL) was incubated for 1 hour at 37°C with isolated, purified membrane lipids from platelet membranes that were immobilized on cover slips to create artificial lipid lamellar structures. The nonbound CRP was washed off and pCRP/mCRP was detected after native PAGE and Western blotting with antibody clone 8. Results were compared to pCRP incubated with nonlipid components of platelets that were in the supernatant of the lipid preparation. Artificially dissociated pCRP, nondissociated pCRP, and membrane lipids without the addition of pCRP served as a control. A typical result out of 3 experiments is shown. F, The CRP dissociation process is not dependent on the platelet-activating agent. Thrombin-stimulated (0.1 U/mL), ADP-stimulated (10 mol/L), or nonstimulated platelets were incubated with 50 g/mL pCRP. Dissociation of pCRP under these conditions was assessed after native PAGE and Western blotting with anti-mCRP antibody 9C9.
In this report, we show that mCRP, but not pCRP, accumulates in human atherosclerotic lesions. We describe a mechanism of pCRP dissociation to mCRP mediated by cell membranes on activated platelets and apoptotic monocytic THP-1 and Jurkat T cells. We further suggest that this structural change in CRP augments inflammatory processes. Overall, we propose a new paradigm for the involvement of CRP in inflammatory processes, in particular in atherosclerosis, via the localized and thus restricted unmasking of the proinflammatory effects of CRP.
Materials and Methods

Reagents and Antibodies
Sodium-azide-free, pCRP, and recombinant mCRP were prepared as described previously. 20 They were filtered trough a 0.2 mol/L Acrodisc and kept in 25 mmol/L Tris-HCl (pH 7.4) plus 0.15 mol/L NaCl and 2 mmol/L CaCl 2 to avoid spontaneous dissociation. mCRP was used in its soluble, citraconylated form. Anti-pCRP antibodies clone 8D8 and 1D6 and anti-mCRP antibody clone 9C9 were provided by Dr Larry Potempa (Acphazin, Deerfield, Ill). pCRP for dissociation assays on platelets and membrane compounds and anti-CRP antibody clone 8 were obtained from Sigma. All reagents were tested for lipopolysaccharide contamination with a Limulus assay (Sigma). Activation-specific anti-Mac-1 single-chain antibody MAN-1 was prepared and used as described previously. 21 Dihydroethidium (DHE) stain was obtained from Molecular Probes. Other antibodies included the following: anti-Fc␥RI clone 10.1 (AbD Serotec), anti-Fc␥RIIa clone IV.3 (Stemcell Technologies), anti-Fc␥RIII clone 3G8 (Immunotech), and goatantimouse horseradish peroxidase antibody (Amersham Bioscience).
An expanded Materials and Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results mCRP in Human Atherosclerotic Plaques
Human atherosclerotic plaques and healthy vessels were stained for mCRP and pCRP. Samples were derived from aortic ( Figure  1 ) and carotid artery plaques (Online Figure I, A and B ). mCRP was detected in fatty streaks and fibrofatty lesions of human aortic atherosclerotic plaques and in carotid artery plaques, whereas pCRP could not be detected. We show positive staining with the anti-CRP antibody clone 8, which stains both mCRP and pCRP. Antibody specificity was confirmed by preabsorption of 9C9 on immobilized mCRP (Online Figure I, B ). mCRP staining correlates with areas that stain for macrophages within the plaque, detected by an anti-CD68 monoclonal antibody (Figure 1 ). Neither form of CRP was detected in healthy vessels, nor were macrophages. mCRP staining was localized extracellularly. Staining for the platelet recep- Figure 3 . A, pCRP dissociation on activated platelet membranes is a fast process. pCRP (50 g/mL) was incubated with activated platelets and dissociation was stopped at indicated time points. mCRP formation was assessed in Western blotting and staining with anti-mCRP antibody clone 9C9. The signal intensity per millimeter squared was quantified by Quantity One software, and background values were subtracted. Signal intensity at 10 minutes was set to 100%. B, Activated platelet membranes lead to complete pCRP dissociation. pCRP (50 g/mL) was incubated overnight with nonactivated and ADPstimulated platelets. mCRP formation and the remaining pCRP were assessed by native PAGE and Western blotting and probing with the conformation-specific antibodies clone 9C9 (anti-mCRP) and clone 8D8 (anti-pCRP). After 12 hours of incubation, all pCRP had been converted to mCRP by activated platelets. Background values were subtracted and maximal signal intensity (quantified by Quantity One software) for 8D8 (pCRP) and for 9C9 (pCRPϩactivated platelets) set to 100%. A typical result out of 3 experiments is shown. C, pCRP dissociation can be facilitated by necrotic/apoptotic Jurkat T and THP-1 cells. Jurkat T and THP-1 cell lines were incubated with H 2 O 2 at various concentrations. Cells were incubated with 50 g/mL pCRP. mCRP formation was assessed by Western blotting and staining for mCRP (clone 9C9).
tor CD41 was negative in healthy vessels but colocalized with mCRP in atherosclerotic plaques from human aorta, as well as carotid artery. In an in vitro model of thrombus formation after incubation with pCRP, mCRP but not pCRP could be histologically detected (Online Figure I, C ), suggesting a dissociation process on activated platelets.
Activated Platelets Transform pCRP Into mCRP, Resulting in Proinflammatory Properties
Native polyacrylamide gel electrophoresis (PAGE) and Western blotting with clone 8 anti-CRP monoclonal antibody were used to investigate whether pCRP dissociates to mCRP (Figure 2A ). mCRP was detected after 1 hour of incubation Figure 4 . A, mCRP leads to increased monocyte activation compared to pCRP. Binding of activation-specific anti-Mac-1 single-chain antibody (MAN-1) to monocytes was detected after incubation with mCRP (black line) or pCRP (light gray line). SEM of 3 experiments is given (#PϽ0.01). Typical histograms are shown for MAN-1 binding after stimulation with 5 g/mL mCRP or 5 g/mL pCRP. Binding to CRP-stimulated monocytes is shown as black overlay over the nonstimulated control (light gray). PMA (100 ng/mL) served as positive control. B, mCRP leads to increased production of ROS in monocytes, compared to pCRP. ROS production was detected by DHE staining after 60 minutes of incubation with various concentrations of mCRP (black line) or pCRP (gray line). SEM of 3 experiments is given (#PϽ0.01). The histograms show typical results of the flow cytometric assays. DHE staining of nonstimulated (gray) monocytes is overlaid by DHE staining of monocytes after incubation with mCRP and pCRP (red). PMA served as positive control. For fluorescence microscopy, monocytes were stimulated with 100 ng/mL PMA, 10 g/mL mCRP, or 10 g/mL pCRP for 30 minutes and stained with DHE staining.
with pCRP at 37°C with purified, ADP-stimulated platelets (Figure 2A) , as well as after incubation with ADP-stimulated whole blood ( Figure 2B ). Dissociation occurred only on activated platelets (Figure 2A) and was independent of the activating agent ( Figure 2F ). Furthermore, mCRP could not be detected in the supernatant of platelets after centrifugation at 2000g for 20 minutes (Figure 2A ), suggesting that mCRP remains adherent to the platelet surface.
Phosphatidylcholine (PC) is the major membrane lipid in eukaryotic cells and serves as a reservoir for several lipid messengers, such as lysophosphatidylcholine (LPC). On activation and cell death, LPC is exposed on membranes and has been shown to bind CRP. 22 As a model for an activated membrane, an immobilized LPC-PC monolayer was used and incubated with native pCRP for 1 hour at 37°C. This led to the dissociation of pCRP to mCRP, which was not observed with PC monolayer alone (Figure 2A) .
The dissociation of pCRP to mCRP on activated platelets and on LPC-PC significantly affects monocyte adhesion. pCRP was dissociated on activated platelets or on an artificial monolayer of LPC-PC. After incubation, the mixture or each individual component was added to purified monocytes and the effect on monocyte adhesion was assessed. Incubation of pCRP with activated platelets led to increased adhesion of monocytes to a fibrinogen matrix ( Figure 2C ). This effect was greater than with pCRP alone, platelets alone, pCRP with nonactivated platelets or activated platelets alone. Thus, the dissociation of pCRP occurs on activated platelets ( Figure  2C ) leading to a several-fold increase in monocyte adhesion. Consistent with the findings in Figure 2A , incubation of pCRP on a LPC-PC lipid monolayer also led to formation of mCRP, which increased monocyte adhesion to fibrinogen ( Figure 2D ). Notably, pCRP incubated with PC did not lead to pCRP dissociation and did not increase monocyte adhesion.
Dissociation of pCRP to mCRP Is Mediated by Membrane Lipids and Dependent on LPC
The aforementioned results suggest that the dissociation process is not receptor-mediated. To further address this hypothesis, Figure 5 . A, mCRP increases monocyte adhesion to fibrinogen in a static adhesion assay. Monocytes were stimulated with various concentrations of either pCRP or mCRP and allowed to adhere to a fibrinogen matrix. PMA-stimulated (100 ng/mL) monocytes served as control. Means and SDs are given for 7 different experiments, each performed in triplicate, and are depicted as percentage of adherent cells compared to the PMA control (100%). Adherent cells were quantified with a phosphatase-substrate assay, and absorbance was read at 405 nm (#PϽ0.05 as compared to control). B, pCRP inhibits mCRPinduced activation of monocytes. Monocytes were preincubated with various concentrations of pCRP for 10 minutes before stimulation with 25 g/mL mCRP and allowed to adhere to a fibrinogen matrix. Means and SDs are given for 3 different experiments (#PϽ0.05, *PϽ0.01 compared to mCRP), each performed in triplicate and depicted as percentage adherent cells compared to mCRP-stimulated monocytes (100%). C, mCRP exerts proinflammatory properties via lipid rafts and Fc␥ receptors involving PI3K and src-kinase signal-transduction pathways. Monocytes were preincubated with either blocking anti-CD16, anti-CD32, anti-CD64, a nonspecific isotype-matched mouse IgG control antibody (all at 2.5 g/mL), 25 g/mL nystatin for the disruption of lipid rafts, or blockers of the PI3K (wortmannin) or src-kinase pathway (PP2) for 10 minutes and then stimulated with 25 g/mL mCRP. Monocytes were then allowed to adhere to fibrinogen. Means and SDs are given for 3 different experiments (#PϽ0.01 as compared to nonstimulated control, *PϽ0.01 as compared to mCRP), each performed in triplicate and are depicted as percentage of mCRP-induced increase in adhesion over nonstimulated monocytes (mCRPϭ100%).
platelets were lysed and membrane lipids isolated and immobilized on cover slips, creating an artificial lipid-surface. As the true physiological structure of the membrane is not present in this model and lipids normally found on the inner membrane leaflet are exposed, the dissociation of pCRP on these membrane lipids was anticipated. Indeed, pCRP is dissociated on isolated platelet membranes ( Figure 2E ). When pCRP was incubated with the supernatant from platelets, containing nonlipid platelet components, pCRP dissociation was not observed. This suggests that the process is independent of nonlipid products and other soluble factors released from platelets on activation.
Dissociation of pCRP to mCRP on Activated Platelets Is a fast and Complete Process That Is Dependent on the Generation of LPC and Is Not Restricted to Platelet Membranes
Coincubation of pCRP with activated platelets results in mCRP generation within a minute and is complete within 12 hours ( Figure 3A and 3B ). Cells other than platelets were able to convert pCRP to mCRP. H 2 O 2 -induced apoptosis of monocytic THP-1 cells and Jurkat T cells results in mCRP generation ( Figure 3C ). See detailed descriptions of these experiments in the Online Data Supplement.
mCRP Is a More Potent Stimulant for Monocytes Than pCRP and Leads to Mac-1 Reactive Oxygen Species Activation and Production
To assess activation of integrin Mac-1, monocytes were incubated with various amounts of either pCRP or mCRP and the binding of the activation-specific Mac-1 antibody MAN-1 21 was measured using flow cytometry. A dose-dependent increase in Mac-1 activation on stimulation with mCRP but not with pCRP ( Figure 4A ) was observed. Production of reactive oxygen species (ROS) is another measure of monocyte activation. Flow cytometry, as well as fluorescence microscopy, was used to evaluate ROS production in monocytes. Compared to pCRP, mCRP was the more potent inductor of ROS production in monocytes ( Figure 4B ).
mCRP Leads to Increased Monocyte Adhesion Under Static Conditions
Confirming the above results of mCRP-stimulation of monocytes and to directly assess concentration dependency, we could demonstrate that mCRP induced a concentrationdependent increase of monocyte adhesion to a fibrinogen matrix, whereas pCRP was clearly less potent ( Figure 5A ).
mCRP Exerts Proinflammatory Properties via Lipid Rafts and Fc␥ Receptors
Static monocyte adhesion induced by mCRP can be partially inhibited by pCRP at high concentrations and by blocking CD64 (Fc␥I), CD32 (Fc␥IIa) and CD16 (Fc␥III) ( Figure 5B and 5C). Interestingly, the disruption of lipid rafts by nystatin 23 causes a complete abortion of mCRP-induced cell adhesion. The blockade of phosphatidylinositol 3-kinase (PI3K) (assessed with the blocker wortmannin) and srckinase (assessed with the src-kinase-specific inhibitor PP2) inhibits mCRP-induced adhesion of monocytes ( Figure 5C ).
pCRP Dissociation to mCRP Is Localized to Adherent, Activated Platelets
We used immunofluorescence microscopy to detect pCRP dissociation on spread, activated platelets ( Figure 6 ). After the addition of pCRP to activated platelets, mCRP can be detected by clone 9C9 staining. The fluorescence signal is localized on and restricted to the platelet surface. The remaining pCRP was detected by antibody 1D6. Figure 6 . pCRP dissociation is localized to adherent platelets. pCRP was added to adherent platelets at 100 g/mL, and pCRP dissociation was assessed by immunofluorescence microscopy with anti-mCRP antibody clone 9C9, anti-pCRP antibody clone 1D6, and a goat anti-mouse-FITC secondary antibody. Platelets stained with both antibodies but without pCRP addition served as control. As a positive control, platelets were incubated with 10 g/mL mCRP. Images were taken at ϫ600 magnification. Right, Digitally magnified areas of the merged differential interference contrast (DIC) and FITC images. pCRP is dissociated to mCRP on adherent platelets. mCRP is localized on the spread platelet membrane (arrow). The remaining pCRP can also be detected on platelets. As a further control, platelets were incubated with mCRP and stained with anti-pCRP antibody 1D6 (bottom). Typical results out of 3 experiments are shown.
Online Data Supplement
The Online Data Supplement (including movie files) demonstrates proinflammatory effects of CRP isoforms on monocytes in a flow chamber assay on human coronary artery endothelial cells, as well as on a platelet monolayer. Monocyte transmigration assays are also described.
Discussion
We describe a new paradigm (Figure 7) for the localized unmasking of the proinflammatory effects of CRP by activated platelets and apoptotic cells and its potential role in atherosclerosis based on the following findings. (1) CRP present in atherosclerotic lesions in human aorta and carotid artery is in the monomeric conformation. (2) Activated platelets found at atherosclerotic lesions can dissociate native pCRP into mCRP, suggesting that pCRP is a potential source of mCRP in atherosclerotic plaques. This conversion process is mediated by the exposure of LPC on the surface of activated platelets and can take place in whole blood. The dissociation of pCRP to mCRP is not limited to platelets but can also be mediated by apoptotic cells. (3) mCRP, but not pCRP, in low concentrations can activate monocytes and can trigger events involved in rolling, adhesion, and finally transmigration. (4) mCRP, but not pCRP, leads to ROS production at low concentrations that are found in the plasma of cardiovascular risk patients. (5) Native pCRP shows proinflammatory properties at high concentrations, suggesting pCRP may be important as a proinflammatory molecule in clinical conditions where high plasma concentrations are found (eg, in septicemia).
CRP has been previously detected in atherosclerotic lesions, typically using antibodies that detect both mCRP and pCRP. 24 In the present study using conformation-specific antibodies, mCRP, and not pCRP, was demonstrated for the first time to colocalize with macrophages in the intima of human atherosclerotic lesions. Although CRP may be generated to a limited extent by cells within the atherosclerotic lesion, 1, 13 it is expected that the majority of CRP in atherosclerotic plaques is derived from circulating CRP. 24, 25 Colocalization with macrophages may suggest an interaction between CRP and monocytes/macrophages as described previously. 26 There has been some in vitro evidence that mCRP can exert proinflammatory effects that are distinct from those of pCRP. 16, 17, 19, 27 Verma et al postulated the existence of a dissociation process for CRP in the peripheral circulation that would locally enhance its proinflammatory properties. 28 We were able to define such a dissociation process, showing that activated platelet membranes exposing the bioactive lipid LPC mediate the dissociation of pCRP to mCRP. This results in a marked increase in proinflammatory properties of CRP, demonstrated by an increase in monocyte adhesion to fibrinogen. Generation of LPC via activation of the Ca 2ϩindependent phospholipase A 2 and exposure of LPC on the cell surface is a mechanism generally found in apoptotic cells 29 and activated platelets. 30 These findings potentially Figure 7 . Proposed mechanism of the platelet-mediated proinflammatory properties of CRP at atherosclerotic plaques. Circulating platelets adhere to the inflamed or injured endothelium and become strongly activated, thereby exposing bioactive lipids on the cell surface. Circulating pCRP binds to phosphocholine on spread platelets and dissociates into mCRP via a LPC-mediated mechanism. mCRP then stimulates circulating monocytes, activates integrin receptors (depicted in green), and leads to monocyte adhesion to receptors on endothelial cells (depicted in orange), production of ROS, and transmigration of monocytes into the intima and the formation of foam cells. mCRP is then deposited into the atherosclerotic plaque. link the novel pathomechanistic role of pCRP to mCRP conversion with emerging data postulating that phospholipase activity and LPC generation are being associated with increased cardiovascular risk. [31] [32] [33] We suggest that CRP circulates as a pentamer, with only mild proinflammatory effects at slightly elevated plasma concentrations (eg, around 5 g/mL) typically found in patients with an elevated cardiovascular risk. On activation and adhesion, platelets undergo a rapid change in morphology and composition of membrane lipids, leading to the exposure of bioactive lipids, such as LPC. 34 Our finding of a crucial role of LPC in the interaction with CRP is supported by several reports. 22, 35 Via interaction with LPC, the close proximity of CRP to the cell membrane layer can result in the dissociation of pCRP to mCRP. 36 Using immunofluorescence microscopy, we show the generation of mCRP from pCRP on adherent activated platelets, which, together with the immunohistological colocalization of mCRP with the CD41 antigen in atherosclerotic plaques, provides further evidence for the important role of activated platelet membranes in the dissociation process. The resulting mCRP itself can lead to increased P-selectin expression on platelets, 37 which in turn might promote monocyte adhesion via binding to P-selectin glycoprotein ligand (PSGL)-1. Thus, we propose that in atherosclerosis mCRP is generated from circulating pCRP, and mCRP is then deposited at the atherosclerotic plaque, exerting strong proinflammatory effects.
For circulating pCRP, several studies have shown proinflammatory properties. 8, 9 However, in the majority of these studies, higher concentrations of pCRP were used, which reflects septicemic situations. This might be fundamentally different from chronic inflammatory processes. Interestingly, the presence of pCRP partially inhibits the effects of mCRP on monocytes when added before mCRP. This could be explained by competition for potential mCRP-binding sites, antiinflammatory effects of pCRP, or direct interaction of pCRP with mCRP. 38 Thus, pCRP may have a regulatory attenuating function on proinflammatory mCRP effects.
It has been suggested that CD32 (Fc␥IIa) and CD64 (Fc␥I) are the main receptors on human leukocytes for pCRP, 11 whereas CD16 (Fc␥III) is thought to mediate some, albeit not all, mCRP effects. 16, 17 Very recently receptor-independent signal transduction has been described through mCRP integration into the membrane at lipid rafts of human aortic and coronary artery endothelial cells. 23 This mechanism may also be functionally relevant in mCRP-induced monocyte activation. We show that proinflammatory effects of mCRP are only slightly reduced after blockade of CD16, CD32 and CD64 receptors, whereas disruption of lipid rafts by nystatin leads to complete inhibition of mCRP-mediated effects. Our findings that inhibition of PI3K and src-kinase blocks the effects of mCRP is consistent with signal transduction mediated by both lipid rafts 39 and by Fc␥R signaling. 40 Overall, our results suggest that both lipid rafts and Fc␥Rs represent potential binding sites for mCRP on monocytes. The role and interaction of both pathways warrants further investigations in particular in regard to their therapeutic targeting.
The newly described mechanism of pCRP dissociation has potential implications beyond that of atherosclerosis and extends to other inflammatory processes that involve tissue damage. Severely damaged or apoptotic cells also expose LPC 22 via a Ca 2ϩ -independent phospholipase A 2 -mediated mechanism. 29 Therefore, the described pCRP dissociation, as shown by us, on H 2 O 2 -treated monocytes, as well as T cells, can potentially also take place at areas of tissue injury and may thus direct inflammatory reactions to these areas.
In conclusion, we postulate that mCRP is an important and potent mediator of inflammatory reactions, such as atherosclerosis. Furthermore, by demonstrating the conversion of pCRP to mCRP on membranes of activated platelets and apoptotic cells, we identify a mechanism that unmasks the proinflammatory properties of CRP. This defines a potential link between circulating CRP, as established cardiovascular risk marker, and localized platelet-mediated inflammatory and potentially proatherogenic reactions. Based on this new paradigm, mCRP itself and/or the conversion process of pCRP to mCRP represent new potential therapeutic targets in the treatment of inflammation and atherosclerosis.
